Biobanking Equipment Market By Equipment Type (Cryogenic Storage Systems, Refrigerators, Ice Machines, Freezers, Alarm Monitoring Systems, Automated Storage Systems, Centrifuges and Biobank Workflow Equipment, Biospecimen Tracking Software), By Sample Handling Process (Collection, Processing, Storage, Distribution), By End-User Industry (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinical Laboratories), and By Region ; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Biobanking Equipment Market was valued at USD 2.9 billion in 2023 and will surpass USD 5.6 billion by 2030; growing at a CAGR of 9.9% during 2024 - 2030.

The biobanking equipment market is a vital sector in the life sciences industry, providing essential tools and technologies for the storage, management, and processing of biological samples. With advancements in genomics, personalized medicine, and regenerative therapies, the demand for robust and efficient biobanking solutions has risen significantly. Equipment such as cryogenic storage systems, automated storage solutions, and biospecimen tracking software are integral to maintaining the integrity and accessibility of stored samples. This market is also expanding as research and pharmaceutical industries increase investments in biobanks for clinical trials, drug discovery, and disease research.

Cryogenic Storage Systems Are the Largest Equipment Segment, Driven by Growing Demand

Cryogenic storage systems, including freezers, ice machines, and refrigerators, dominate the biobanking equipment market due to their critical role in maintaining the viability of biological samples. These systems operate at ultra-low temperatures to preserve specimens like stem cells, DNA, and tissues for extended periods without degradation. As biobanks expand globally, especially in the fields of regenerative medicine and genomics, the demand for reliable cryogenic storage has increased. Freezers are particularly sought after for their ability to store large volumes of specimens in a controlled environment, ensuring sample integrity.

The continuous development of cryogenic storage technology, such as energy-efficient systems and automation capabilities, is also fueling market growth. Innovations that reduce energy consumption while ensuring optimal storage conditions are becoming a key competitive advantage for equipment manufacturers. Companies that invest in high-performance, low-maintenance, and smart cryogenic storage systems are well-positioned to meet the growing needs of research institutes, hospitals, and pharmaceutical companies involved in long-term storage of biospecimens.

Collection Process Is Fastest Growing Segment, Due to Technological Advancements in Sampling

The collection process segment in biobanking equipment is growing at the fastest rate, driven by innovations in automated and precision sampling technologies. The process of collecting biological samples, such as blood, saliva, or tissue, is becoming more efficient and accurate with the use of automated systems that minimize human error. These systems are increasingly being integrated into biobank workflows, enhancing the speed and reliability of sample collection.

Furthermore, the expansion of precision medicine, which requires high-quality, standardized samples for research and clinical trials, has further boosted the demand for advanced collection tools. As global biobanks scale their operations, the automation of sample collection allows for higher throughput while reducing costs associated with manual labor and variability in sample quality. This trend is expected to continue as biobanks evolve to meet the needs of pharmaceutical companies and research institutions focusing on drug discovery and personalized medicine.

Pharmaceutical and Biotechnology Companies Drive End-User Industry Growth

Pharmaceutical and biotechnology companies are the largest end-users of biobanking equipment, owing to their need for high-quality biological samples in drug discovery and clinical research. These industries rely heavily on biobanks to provide well-preserved samples for testing and the development of new therapies, especially in areas such as oncology, neurology, and immunology. Biobanks are essential for conducting studies that involve large sample sizes, as they provide access to diverse and well-documented biological specimens, enabling companies to accelerate drug development timelines.

The growing focus on personalized medicine, which requires tailored treatments based on genetic and molecular information, is also propelling the demand for biobanks. As biopharmaceutical companies continue to invest in gene therapies, stem cell research, and other advanced treatments, biobank operators are expected to provide increasingly sophisticated storage solutions to meet the demands of these high-growth sectors.

North America Leads Biobanking Equipment Market, Supported by Advanced Healthcare Infrastructure

North America, particularly the United States and Canada, remains the largest regional market for biobanking equipment. The region’s strong healthcare infrastructure, extensive research activities, and well-established pharmaceutical and biotechnology industries contribute to its dominant position. Moreover, the rising prevalence of chronic diseases, the growing emphasis on personalized medicine, and significant government investments in healthcare innovation further support the demand for biobanks in the region.

The U.S. leads North America in terms of both the number of biobanks and their technological capabilities. Leading research institutions, hospitals, and universities in the U.S. are adopting state-of-the-art biobanking solutions, which include automated sample handling systems and advanced cryogenic storage technologies. This growth is further driven by funding programs and grants from the government and private sector aimed at supporting biomedical research and clinical trials.

Competitive Landscape: Leading Companies Driving Market Growth

The biobanking equipment market is highly competitive, with several key players leading technological advancements and product innovations. Companies such as Thermo Fisher Scientific, Qiagen, Brooks Life Sciences, and Hamilton Company are prominent in the market, offering a range of products, including cryogenic storage systems, automated storage solutions, and biospecimen tracking software. These companies are investing heavily in research and development to enhance the efficiency, reliability, and performance of their products, catering to the growing needs of biobank operators across the globe.

Moreover, strategic partnerships, mergers, and acquisitions are common in the industry as companies aim to expand their product offerings and market presence. For example, Thermo Fisher Scientific’s acquisition of Patheon has strengthened its position in the pharmaceutical and biotechnology sectors, providing an integrated solution for drug discovery and development that includes biobanking services. With the rising demand for biobank services, competition is intensifying, and companies are focusing on building comprehensive product portfolios to cater to the diverse needs of biobank operators worldwide.

Recent Developments:

• Thermo Fisher Scientific introduced a cutting-edge ultra-low temperature freezer designed to reduce energy consumption by 50%.
• Hamilton Company announced a collaboration with academic institutions to develop AI-powered biobanking workflow solutions.
• BioLife Solutions completed the acquisition of SAVSU Technologies, enhancing its product portfolio in cryogenic storage.
• Eppendorf AG launched a next-generation centrifuge optimized for biobank sample processing.
• Haier Biomedical received regulatory approval for its biobank automation system, expanding its global reach.

List of Leading Companies:

• Thermo Fisher Scientific
• Qiagen
• Brooks Life Sciences
• Hamilton Company
• Tecan Trading AG
• BioLife Solutions
• BD Biosciences
• Eppendorf AG
• STEMCELL Technologies
• LabVantage Solutions
• Panasonic Healthcare Holdings
• VWR International
• Promega Corporation
• Haier Biomedical
• Beckman Coulter

Report Scope: